Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riliprubart (Primary)
  • Indications Demyelinating disorders; Polyneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms VITALIZE
  • Sponsors Sanofi

Most Recent Events

  • 27 Oct 2025 Planned End Date changed from 19 Nov 2027 to 12 Jan 2029.
  • 27 Oct 2025 Planned primary completion date changed from 5 Nov 2025 to 9 Jul 2027.
  • 19 Aug 2025 Planned End Date changed from 19 May 2027 to 19 Nov 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top